.jpeg)
2026-08-26 07:04:50
Revumenib (brand name: REVUFORJ) is a leading oral menin inhibitor designed for relapsed/refractory acute leukemias with KMT2A translocations or NPM1 mutations. This article explores its innovative mechanism of blocking aberrant protein interactions, correcting leukemogenic transcription programs, and outlines key clinical indications and safety management.
2026-08-26 07:02:04
Pretomanid is a novel anti-tuberculosis agent used in combination with bedaquiline and linezolid as the BPaL regimen for drug-resistant TB. This guide outlines the adverse effect profile of the combination, key safety monitoring points, and clinical management strategies to help clinicians and patients navigate treatment risks.
2026-08-25 08:20:48
Asciminib (brand name: Scemblix) is the world's first approved BCR-ABL1 allosteric inhibitor, offering a novel treatment option for chronic myeloid leukemia. This guide outlines its targeted mechanism of action, indication-specific dosing, missed-dose protocols, and key safety monitoring points.
2026-08-25 08:14:06
Vigabatrin (brand name: Sabril) is the first irreversible GABA transaminase inhibitor, holding a unique place in the treatment of infantile spasms and refractory complex partial seizures. This guide provides a comprehensive overview of its chemistry, mechanism, pharmacokinetics, dosing protocols, vision risk management, and drug interactions for clinicians and caregivers.
2026-08-25 08:10:21
Belzutifan (WELIREG) is a first-in-class oral HIF-2α inhibitor approved for VHL-associated renal cell carcinoma, CNS hemangioblastomas, and pancreatic neuroendocrine tumors. This guide outlines dosing, time to response, follow-up schedules, discontinuation criteria, and long-term management strategies for patients and clinicians.
2026-08-24 07:51:59
Lapatinib is an oral dual HER2/EGFR tyrosine kinase inhibitor. Key adverse effects to monitor during treatment include diarrhea, skin reactions, and hepatic function changes. This article outlines recognition points and graded management strategies.
2026-08-24 07:41:38
Trelagliptin is a long-acting DPP-4 inhibitor taken orally just once a week. By prolonging the action of incretin hormones, it helps regulate blood glucose levels, offering a more convenient dosing option for adults with type 2 diabetes.
2026-08-24 07:36:03
Two neurokinin receptor antagonists—fezolinetant and elinzanetant—have been approved as non-hormonal therapies for menopausal vasomotor symptoms. Data from the 2026 NIRVANA trial further confirm elinzanetant's efficacy in improving menopause-related sleep disturbances.
2026-08-21 03:30:56
Cemiplimab is a PD-1 immune checkpoint inhibitor that restores T-cell antitumor immunity. It is FDA-approved for advanced basal cell carcinoma, cutaneous squamous cell carcinoma, and selected cases of non-small cell lung cancer.
2026-08-21 03:11:31
Nintedanib (brand name OFEV) is a multi-target tyrosine kinase inhibitor that slows the decline of lung function by blocking key profibrotic signaling pathways. It is FDA-approved for idiopathic pulmonary fibrosis (IPF), progressive fibrosing interstitial lung disease (PF-ILD), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
2026-08-20 03:48:01
Capmatinib (brand name Tabrecta) is a highly selective MET tyrosine kinase inhibitor developed by Novartis, approved for adults with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations. This article systematically examines its positioning as a second-generation MET inhibitor with superior selectivity and intracranial activity, provides detailed adverse effect incidence data from the pivotal GEOMETRY mono-1 trial, and presents grade-based management strategies for peripheral edema, hepatotoxicity, gastrointestinal effects, and other toxicities, along with dose-modification protocols and special-population guidance to support safe and effective targeted therapy.
2026-08-20 03:28:50
Gilteritinib (brand name XOSPATA) is a highly selective oral FLT3 inhibitor developed by Astellas Pharma, approved for FLT3-mutated relapsed or refractory acute myeloid leukemia (AML). This article provides a structured overview of the drug's development and manufacturing background, the standard 28-day dosing cycle, individualized treatment duration decisions, efficacy assessment milestones, dose-modification and interruption protocols, and practical daily-life management guidance to help patients and families plan treatment schedules and follow-up visits effectively.
